Our biotech columnist live-blogged the outside panel of cancer experts convened by the FDA reviews Cell Therapeutics' lymphoma drug pixantrone on Monday; read on to review the action.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.